More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

Lawrence-based Deciphera Pharmaceuticals LLC is teaming up with Eli Lilly and Co. to license and develop technology designed to fight cancer, in a partnership announced Friday that ultimately could ...

Last May, Deciphera Pharmaceuticals’ Qinlock became the first drug the FDA specifically approved for heavily pretreated patients with gastrointestinal stromal tumor. But now, a trial flop has squashed ...

(Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States ...

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline. DCC-3084, a pan-RAF inhibitor, “is no longer in our pipeline and we ...

On a bad day for the stock market overall, Deciphera Pharmaceuticals (NASDAQ: DCPH) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch of a ...

A Lawrence drug development firm has received a $7 million payment from pharmaceutical giant Eli Lilly and Co. for work on research that could lead to a new drug to fight cancer. Leaders with Lawrence ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection ...